Table 1.

List of studies assessing Venetoclax in association with other agents in acute myeloid leukemia. AZA—azacitidine; BETi—BET inhibitor; CLA—cladribine; CCML—chronic myelomonocytic leukemia; COB—cobimetinib; DEC—decitabine; ENA—enasidenib; FLAG—fludarabine; G-CSF—Granulocyte colony-stimulating factor; GILT—gilteritinib; HIDAC—high-dose cytarabine; HMA—hypomethylating agent; IDA—idarubicin; IDASA—idasanutlin; IVO—ivosidenib; LINT-AC225—lintuzumab-Ac225; LDAC—low dose cytarabine; MAGRO—magrolimab; MCL1i—MCL1 inhibitor; MDS—myelodysplastic syndrome; MEKi—MEK inhibitor; MIDO—midostaurin; MIVE—mivebresib; SAB—sabatolimab; SORA—sorafenib; TAGR—tagraxofusp; VEN—venetoclax.

Agents in Combination with VEN	Population	Phase Study	References
VEN plus HMA/LDAC
AZA	ND AML ineligible for IC	3	27
LDAC	ND AML ineligible for IC	3	33
Intensive Chemotherapy
7 + 3	ND AML	1b	NCT03709758
7 + 3	ND AML and MDS-EB	3	NCT04628026
CLA, HIDAC, IDA	ND AML, HR-MDS, and MPAL	2	34
5 + 2	ND AML ≥ 65 years old	1b	35
FLAG-IDA	ND and R/R-AML	1b/2	36–37
CPX-351	ND AML	1b	NCT04075747
‘Non-Intensive’ Combinations
GILT	R/R FLT3 mutated AML	1	42
AZA plus GILT	R/R and ND AML/high risk CMML/MDS FLT3-ITD or -TKD mutated	½	43
DEC and FLT3i (GILT/SORA/MIDO)	ND or R/R FLT3 mutated AML	2	44
IVO and AZA	MDS, ND, and R/R AML IDH1+	1b/2	49
ENA	R/R AML IDH2+	1b/2	50
AZA and MAGRO	R/R AML, ND AML IC ineligible	1/2	NCT04435691
MIVE (pan-BETi)	R/R AML	1	NCT02391480
S64315 (MCL1i)	R/R Hematological malignancies	1	NCT03672695
IDASA	R/R AML ≥ 60 years old	1b	77
GO	R/R AML	1b	94
TAGR plus AZA	ND and R/R AML, MDS, or BPDCN	1b	111
LINT-AC225	R/R AML	1/2	119
SAB	High or very high risk MDS	2	NCT04812548
COB (MEKi)	R/R AML ≥ 60 years old, IC ineligible	1b	207
CA-4948	R/R AML and high risk MDS	1/2a	NCT04278768